Pioglitazone and Quetiapine XR Pharmacogenetic Study
Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.
Major Depressive Disorder
|Study Design:||Time Perspective: Retrospective|
|Official Title:||Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders|
- Genetic markers associated with treatment response [ Time Frame: Up to 1.5 years ] [ Designated as safety issue: No ]Genetic markers in PPARG, 5-HT2A, CYP3A4 and CYP2C8 genes known to be related in the pharmacodynamics and pharmacokinetics of pioglitazone or quetiapine XR will be associated with treatment response.
|Study Start Date:||February 2011|
|Estimated Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
Participants who received Seroquel
Participants who received pioglitazone
Please refer to this study by its ClinicalTrials.gov identifier: NCT01342380
|United States, Ohio|
|University Hospitals Case Medical Center|
|Cleveland, Ohio, United States, 44106|
|Principal Investigator:||Jinbo Fan, PhD||Case Western Reserve University|